Compare JAGX & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAGX | BGLC |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | Malaysia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 4.4M |
| IPO Year | 2014 | 2019 |
| Metric | JAGX | BGLC |
|---|---|---|
| Price | $0.87 | $1.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $60.00 | N/A |
| AVG Volume (30 Days) | ★ 104.5K | 6.2K |
| Earning Date | 04-07-2026 | 04-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.42 | 45.78 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,511,000.00 | $7,424,911.00 |
| Revenue This Year | $61.58 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.22 | $1.07 |
| 52 Week High | $8.00 | $6.10 |
| Indicator | JAGX | BGLC |
|---|---|---|
| Relative Strength Index (RSI) | 24.13 | 48.38 |
| Support Level | $0.60 | $1.55 |
| Resistance Level | $0.99 | $2.15 |
| Average True Range (ATR) | 0.09 | 0.08 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 9.01 | 90.48 |
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.